相似文献
1
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.
Pneumonia (Nathan). 2021 Dec 6;13(1):14. doi: 10.1186/s41479-021-00092-9.
2
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
CellR4 Repair Replace Regen Reprogram. 2020;8. doi: 10.32113/cellr4_20204_2839. Epub 2020 Apr 28.
3
The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Stem Cells Transl Med. 2020 Nov;9(11):1287-1302. doi: 10.1002/sctm.20-0164. Epub 2020 Jul 21.
4
COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review).
Iran J Microbiol. 2021 Dec;13(6):737-747. doi: 10.18502/ijm.v13i6.8072.
5
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Trials. 2021 Feb 28;22(1):170. doi: 10.1186/s13063-021-05118-7.
6
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Anal Cell Pathol (Amst). 2020 Nov 20;2020:1939768. doi: 10.1155/2020/1939768. eCollection 2020.
7
COVID-19 pandemic: overview of protective-ventilation strategy in ARDS patients.
Acta Clin Belg. 2021 Dec;76(6):509-511. doi: 10.1080/17843286.2020.1761162. Epub 2020 Apr 27.
8
Ventilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2.
J Clin Med. 2023 Dec 5;12(24):7509. doi: 10.3390/jcm12247509.
9
Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Expert Rev Respir Med. 2021 Mar;15(3):301-324. doi: 10.1080/17476348.2021.1848555. Epub 2020 Nov 26.
10
The Basics of ARDS Mechanical Ventilatory Care for Cardiovascular Specialists.
Can J Cardiol. 2020 Oct;36(10):1675-1679. doi: 10.1016/j.cjca.2020.07.011. Epub 2020 Jul 23.
引用本文的文献
1
Inhibition of Inflammatory Regulators for Chronic Obstructive Pulmonary Disease (COPD) Treatment from Indonesian Medicinal Plants: A Systematic Review.
Curr Issues Mol Biol. 2025 Apr 8;47(4):262. doi: 10.3390/cimb47040262.
2
The cholinergic drug galantamine ameliorates acute and subacute peripheral and brain manifestations of acute respiratory distress syndrome in mice.
bioRxiv. 2025 May 22:2025.05.17.654675. doi: 10.1101/2025.05.17.654675.
3
Plasma metabolomics signatures predict COVID-19 patient outcome at ICU admission comparable to clinical scores.
Sci Rep. 2025 May 3;15(1):15498. doi: 10.1038/s41598-025-00373-z.
4
Assessment of Knowledge, Perception, Experience, and Phobia Toward Corticosteroids Among the General Public in Two Southeast Asian Countries.
Inquiry. 2025 Jan-Dec;62:469580251333968. doi: 10.1177/00469580251333968. Epub 2025 Apr 24.
5
Sex-related differences in the association between migraine, COVID-19, and long COVID: a population-based cohort.
Front Neurol. 2025 Mar 21;16:1547893. doi: 10.3389/fneur.2025.1547893. eCollection 2025.
6
Nanoparticles of natural product-derived medicines: Beyond the pandemic.
Heliyon. 2025 Feb 19;11(4):e42739. doi: 10.1016/j.heliyon.2025.e42739. eCollection 2025 Feb 28.
7
Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.
Infect Dis Rep. 2025 Feb 5;17(1):11. doi: 10.3390/idr17010011.
8
The ZNF717-rs2918520 genotype contributes to COVID-19 severity: a Taiwanese cohort study.
BMC Infect Dis. 2025 Feb 11;25(1):201. doi: 10.1186/s12879-025-10551-z.
9
COVID-19 in the years 2020 to 2022 in Germany: effects of comorbidities and co-medications based on a large-scale database analysis.
BMC Public Health. 2025 Feb 8;25(1):525. doi: 10.1186/s12889-024-21110-7.
10
A Technique for Monitoring Mechanically Ventilated Patient Lung Conditions.
Diagnostics (Basel). 2024 Nov 21;14(23):2616. doi: 10.3390/diagnostics14232616.
本文引用的文献
1
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.
EClinicalMedicine. 2021 Jun 17;37:100957. doi: 10.1016/j.eclinm.2021.100957. eCollection 2021 Jul.
2
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
J Infect Public Health. 2021 Aug;14(8):1001-1009. doi: 10.1016/j.jiph.2021.06.004. Epub 2021 Jun 15.
3
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Leukemia. 2021 Sep;35(9):2616-2620. doi: 10.1038/s41375-021-01266-6. Epub 2021 May 14.
4
Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
J Transl Med. 2021 May 10;19(1):198. doi: 10.1186/s12967-021-02862-x.
5
Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review.
Ther Clin Risk Manag. 2021 Apr 28;17:371-387. doi: 10.2147/TCRM.S301817. eCollection 2021.
6
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
Sci Rep. 2021 Apr 27;11(1):9023. doi: 10.1038/s41598-021-88509-9.
7
Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.
Intensive Care Med. 2021 May;47(5):521-537. doi: 10.1007/s00134-021-06394-2. Epub 2021 Apr 19.
8
Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.
BMC Infect Dis. 2021 Apr 10;21(1):337. doi: 10.1186/s12879-021-06045-3.
9
A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.
Intern Emerg Med. 2021 Nov;16(8):2181-2191. doi: 10.1007/s11739-021-02734-8. Epub 2021 Apr 10.
10
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Health Policy. 2021 May;125(5):553-567. doi: 10.1016/j.healthpol.2021.03.013. Epub 2021 Mar 26.
Zotero 插件